[Skip to Content]
[Skip to Content Landing]
Views 115
Citations 0
Comment & Response
March 12, 2020

Frequentist Analysis of Death Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Therapy—Reply

Author Affiliations
  • 1Department of Ophthalmology, University of Catania, Catania, Italy
  • 2Eye Unit, Southampton University Hospital, Southampton, United Kingdom
  • 3Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze, Florence, Italy
  • 4Azienda Ospedaliero Universitaria Careggi, Florence, Italy
JAMA Ophthalmol. Published online March 12, 2020. doi:10.1001/jamaophthalmol.2020.0289

In Reply We are grateful to Fau et al for conducting and providing further analyses on our data set,1 which reinforced our interpretation and the need for further investigation regarding long-term, intensive intravitreal anti–vascular endothelial growth factor (anti-VEGF) treatment. Specifically, the authors remarked on our finding of a potential increase in overall mortality in the subgroup with monthly injections for up to 24 months (odds ratio, 1.89 [95% CI, 1.06-3.36]), which is a key finding of our study.1 However, we have been conservative in drawing conclusions, because despite a relatively large sample size (8887 trial participants), the number of deaths was only 128 (1.44%). Unsurprisingly, a contrast comparing the 6-month follow-up subgroup and the 24-month follow-up subgroup was not significant in the frequentist meta-analysis. This result was confirmed by bayesian methods.1

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×